Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Slides:

Advertisements

Similar presentations

Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary.

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin.

A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio Anna Maria Fulghesu, M.D., Mario Ciampelli,

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome Silvia Ajossa, M.D., Stefano Guerriero, M.D.,

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives George Mastorakos,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic.

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot.

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Differential lipopolysaccharide (LPS)-stimulated TNFα release from mononuclear cells (MNC) of normal weight vs. obese women with polycystic ovary syndrome.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth.

Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome Héctor F. Escobar-Morreale,

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Endocrine and chronobiological effects of fasting in women

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis Shiqin Zhu, M.D., Bingqian Zhang, M.D.,

Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action Vanita Aroda, M.D., Theodore.

Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity Jean-Patrice Baillargeon, M.D.,

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome Macarena Alpañés, M.D., Manuel.

Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women.

Increased secretion of amylin in women with polycystic ovary syndrome

Massimo Tartagni, M. D. , Luca Maria Schonauer, M. D

Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels Antoni J. Duleba, M.D., Beata Banaszewska, M.D.,

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome Carlos Moran, M.D.,

Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation.

Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than.

Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women.

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Serum resistin levels in women with polycystic ovary syndrome

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome Derek A Haas, M.D., Bruce.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin Elsy Velázquez M, M.D.,

Dijana Hadžiomerović, M. D. , Bernhard Rabenbauer, M. D

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Are patients with idiopathic hirsutism (IH) insulin resistant

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Anna Maria Fulghesu, M. D. , Mario Ciampelli, M. D. , Giuseppe Muzj, M

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome C.J Glueck, M.D., Ping.

Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions Kristen Farrell, M.S.,

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy Helena J. Teede, Ph.D., Caroline Meyer, Ph.D.,

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome Kevin H. Maas, M.D., Ph.D., Sandy Chuan,

Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Basak Yildirim, M.D., Nuran Sabir,

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3 Wendy Chang, M.D.,

Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity?

Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M

Enrico Carmina, M.D., Rogerio A Lobo, M.D. Fertility and Sterility

Presentation transcript:

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome Franca Fruzzetti, M.D., Chiara Bersi, M.D., Donatella Parrini, M.D., Cabiria Ricci, M.D., Andrea Riccardo Genazzani, M.D., Ph.D. Fertility and Sterility Volume 77, Issue 5, Pages 936-944 (May 2002) DOI: 10.1016/S0015-0282(02)02955-2

FIGURE 1 Mean (±SE) and individual menstrual cycle length (open circle) before and after 3 and 6 months of naltrexone treatment (50 mg/day). Fruzzetti. Chronic naltrexone administration in PCOS. Fertil Steril 2002. Fertility and Sterility 2002 77, 936-944DOI: (10.1016/S0015-0282(02)02955-2)

FIGURE 2 Individual fasting glucose:insulin ratio before and after 6 months of naltrexone treatment in seven women with PCOS and insulin resistance (G:I <4.5). Mean values (±SE) are also reported. ∗P<.01 vs. baseline values. Fruzzetti. Chronic naltrexone administration in PCOS. Fertil Steril 2002. Fertility and Sterility 2002 77, 936-944DOI: (10.1016/S0015-0282(02)02955-2)

FIGURE 3 Mean (±SE) of basal insulin levels after glucose load in healthy controls (open bar) and in seven women with PCOS and insulin resistance (G:I <4.5; shaded bar). Women with PCOS were studied before and during naltrexone treatment. Values are expressed as area under the curve (insulin AUC). ∗P<.05 patients with PCOS during treatment vs. baseline values. ∗∗P<.001 controls vs. patients with PCOS at baseline. Fruzzetti. Chronic naltrexone administration in PCOS. Fertil Steril 2002. Fertility and Sterility 2002 77, 936-944DOI: (10.1016/S0015-0282(02)02955-2)